25-하이드록시콜레스테롤
25-하이드록시콜레스테롤 · Cholest-5-ene-3β,25-diol · 25-Hydroxycholesterol · 5-Cholesten-3β,25-diol · Cholesterol 25-Hydroxy · Perampanel Impurity 39 · 5-cholestene-3β,25-diol · 5-CHOLESTEN-3β, 25-DIOL

식별자 및 물리적 특성
| CAS No. | 2140-46-7 |
|---|---|
| 분자식 | C27H46O2 |
| 평균 분자량 | 402.7 g/mol |
| 단동위원소 질량 | 402.34978071 g/mol |
| SMILES | C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |
| InChIKey | INBGSXNNRGWLJU-ZHHJOTBYSA-N |
| PubChem CID | 65094 |
| ChEMBL | CHEMBL169046 |
| ChEBI | CHEBI:42977 |
| EC No. | 635-752-4 |
| DTXSID | DTXSID5044023 |
| 현지명 | 25-하이드록시콜레스테롤 |
화학 및 물리적 성질
| XLogP | 6.8 |
|---|---|
| 극성 표면적 | 40.5 |
| 수소 결합 공여자 수 | 2 |
| 수소 결합 수용자 수 | 2 |
| 회전 가능 결합 수 | 5 |
| 무거운 원자 수 | 29 |
| 형식 전하 | 0 |
| 복잡도 | 636 |
| 의약품 | Pharmaceuticals -> Listed in ZINC15 |
| 지질 | Lipids -> Sterol Lipids [ST] -> Sterols [ST01] -> Cholesterol and derivatives [ST0101] |
| Endocrine Disruptors | Potential endocrine disrupting compound |
| Collision Cross Section | 202.81 Ų [M-H]- [CCS Type: DTMethod: single field calibrated with Agilent tune mix (Agilent)] |
| 녹는점 | 177-179 °C |
| 끓는 점 | 513.1±23.0 °C(Predicted) |
| 밀도 | 1.03±0.1 g/cm3(Predicted) |
| 저장 조건 | -20°C |
| 용해도 | 클로로포름: 50mg/mL, 투명, 무색 내지 약간 노란색 |
| pKa(산도 계수) | 15.03±0.70(Predicted) |
| 물리적 상태 | 고체 |
| 색상 | 흰색 또는 연한 노란색 |
| 생물학적 소스 | synthetic (organic) |
| Merck | 13,4846 |
| BRN | 3161259 |
| 안정성 | 제공된 대로 구매일로부터 1년 동안 안정적입니다. DMSO 또는 에탄올 용액은 -20°에서 최대 3개월 동안 보관할 수 있습니다. |
| InChIKey | INBGSXNNRGWLJU-ZHHJOTBYSA-N |
| SMILES | [C@@]12([H])CC[C@H]([C@H](C)CCCC(O)(C)C)[C@@]1(C)CC[C@]1([H])[C@@]3(C)CC[C@H](O)CC3=CC[C@@]21[H] |&1:0,4,5,14,18,20,24,30,r| |
화학적 성질
Off-White Solid
안전 및 규제
| GHS 분류 | WarningH302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]P260, P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P317, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 39 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| 규제 정보 | Cholest-5-ene-3,25-diol, (3.beta.)-: Does not have an individual approval but may be used under an appropriate group standard |
| Hazard Classes and Categories | Acute Tox. 4 (100%) |
| 수질 위해 등급(WGK) | 3 |
| 관세 코드 | 29062990 |
| 위험 문구(R) | 20/21/22-36/37/38-48 |
| 위험 표시 | Xn |
| 안전 문구(S) | 26-36-45 |
| 저장 분류 | 11 - Combustible Solids |
용도
개요
25-hydroxy Cholesterol is an oxysterol. It is formed from cholesterol by cholesterol-25-hydroxylase, and its production can be induced by inflammation or infection. 25-hydroxy Cholesterol suppresses endogenous cholesterol synthesis by binding to insulin-induced gene (INSIG) proteins and preventing sterol regulatory element binding proteins (SREBPs) from being transported to the Golgi. It inhibits IgA class switching induced by LPS and various cytokines in B cells (IC50 = ~50 nM). 25-hydroxy Cholesterol inhibits replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Vero cells (EC50 = 3.675 μM) and reduces increases in viral protein production in infected Vero cells when used prior to infection. It reduces viral RNA loads in the lung and trachea in a mouse model of SARS-CoV-2 infection when administered at a dose of 100 mg/kg per day. Serum levels of 25-hydroxy cholesterol are increased in mice expressing human angiotensin-converting enzyme 2 (hACE2), the functional receptor for SARS-CoV-2, in a model of SARS-CoV-2 infection and in a patient with COVID-19, the primarily respiratory disease caused by SARS-CoV-2.
용도
25-Hydroxycholesterol was used to treat mouse neuroblastoma cells to activate the ABCA1 signaling and in studies related to fatty acid metabolism.
일반 설명
25-hydroxy-cholesterol is a side chain substituted oxysterol. Avanti′s unique sterol reverses cataracts in mice. Gestwicki′s team ...... settled on compound 29, a steroid found naturally in the bloodstream but not in the lens, which has no blood supply. Mice with age-related and hereditary cataracts received drops in the right eye, whereas the left eye went untreated. After just a few weeks, the treated eye was visibly clearer, says Gestwicki, who conducted the work while at the University of Michigan. Cataract severity is measured on a scale of zero to four, with four being the worst case. On average, mice in the study had about a one-grade improvement in cataract severity after 4 weeks of treatment. Science DOI: 10.1126/science.aad7400 It has been recently shown that activation of a macrophage toll-like receptor (TLR) by microbial antigens induces synthesis of 25-hydroxycholesterol, and that this oxysterol potently suppresses IgA production.